Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Outcomes of Hypoferritinemia Without Anemia in Reproductive Age Females
NCT06437080Completed
- Sponsor
- Akram Medical Complex
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ferric carboxymaltose (3 arms), sponsored by Akram Medical Complex. Primary endpoints: Serum ferritin levels at Week 16 and Changes in symptom severity at Week 16. Started Oct 2022; status: completed.
02
Drugs
ferric carboxymaltose
Beyond the preview
Go deeper on NCT06437080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437080.